Seminars in Oncology
Volume 29, Issue 3 , Pages 286-293 , June 2002

Doctor's dilemma: Incorporating tumor markers into clinical decision-making

References 

  1. Stockler MR, Boyd NF, Tannock IF. Guide to studies of diagnostic tests, prognostic factors and treatments. In: ed 3.  Tannock IF,  Hill RP editor. The Basic Science of Oncology. New York: NY, McGraw Hill; 1998;p. 466–492
  2. In: ed 3.  Shah CP editors. Public Health and Preventive Medicine in Canada. Toronto, Canada: University of Toronto Press; 1994;
  3. Nystrom L, Rutqvist LE, Wall S, et al.  Breast cancer screening with mammography: Overview of Swedish randomized trials. Lancet. 1993;341:973–978
  4. Kerlikowske K. Efficacy of screening mammography among women aged 40-49 years and 50 to 69 years: Comparison of relative and absolute benefit. J Natl Cancer Inst Monogr. 1997;22:19–86
  5. Shapiro S. Periodic screening for breast cancer: The HIP randomized controlled trial. J Natl Cancer Inst Monogr. 1997;22:27–30
  6. Hankey BF, Feuer EJ, Legg LX, et al.  Cancer surveillance series: Interpreting trends in prostate cancer—Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91:1017–1024
  7. Carroll P, Coley C, McLeod D, et al.  Prostate-specific antigen best practice policy—Part I: Early detection and diagnosis of Prostate Cancer. Urology. 2001;57:217–224
  8. Gohagan JK, Prorok PC, Barnett DK, et al.  Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. J Urol. 1994;152:1905–1909
  9. George SL. Statistical considerations and modeling of clinical utility of tumor markers. Hematol Oncol Clin North Am. 1994;8:457–470
  10. Bosl GJ, Geller NL, Cirrincione C, et al.  Serum tumor markers in patients with metastatic germ cell tumors of the testis. A 10-year experience. Am J Med. 1983;75:29–35
  11. Price A, Nicholls J, Norman A, et al.  Tumor marker relapse in patients with non-seminomatous germ cell tumors. Ann Oncol. 1994;5:63
  12. In:  Fleming I editors. AJCC Cancer Staging Handbook. Philadelphia, PA: Lippincott-Raven; 1997;p. 225–230
  13. International Germ Cell Cancer Collaborative Group . International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997;15:594–603
  14. Partin AW, Katton MW, Subong EN, et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. JAMA 277:1445-1451
  15. Kattan MW, Eastham JA, Stapleton AM, et al.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766–771
  16. Tannock IF, Osoba D, Stockler MR, et al.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative endpoints. J Clin Oncol. 1996;14:1756–1764
  17. Dowling AJ, Panzarella T, Ernst DS, et al.  A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer. Ann Oncol. 2001;12:773–778
  18. Scher HI, Kelly WM, Zhang ZF, et al.  Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst. 1999;91:244
  19. Fletcher RH. Carcinoembryonic antigen. Ann Intern Med. 1986;104:66–73
  20. Schwartz MK:, Cancer markers . In:  De Vita VT,  Hellman S,  Rosenberg SA, et al. editor. Cancer: Principles and Practice of Oncology. Philadelphia, PA,: Lippincott; 1993;p. 531–542
  21. Desch CE, Benson AB, Smith TJ, et al.  Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol. 1999;17:1312–1321
  22. Nordic Gastrointestinal Tumor Adjuvant Therapy Group . Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomized trial. J Clin Oncol. 1992;10:904–911
  23. Allen-Mersh TG, Earlam S, Fordy C, et al.  Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet. 1994;344:1255–1260
  24. Ackland SP, Moore M, Jones M, et al.  A meta-analysis of two randomized trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Proc Am Soc Clin Oncol. 2001;20:132; (abstr)
  25. ASCO Expert Panel . Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer: Report of the American Society of Clinical Oncology Expert Panel. J Clin Oncol. 1996;14:2843–2877
  26. Bast RC, Ravdin P, Hayes DF, et al.  2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865–1878
  27. Bruinvels DJ, Stiggelbout AM, Keivit J, et al.  Followup of patients with colorectal cancer. Ann Surg. 1994;219:174–182
  28. Rosen M, Chan L, Beart RW, et al.  Follow-up of colorectal cancer: A meta-analysis. Dis Colon Rectum. 1998;41:1116–1126
  29. Moertel CG, Fleming TR, Macdonald JS, et al.  An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 1993;270:943–947
  30. Graham RA, Wang S, Catalano PJ, et al.  Postsurgical surveillance of colon cancer: Preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Ann Surg. 1998;228:59–63
  31. Trigo JM, Tabernero JM, Paz-Ares L, et al.  Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer. 2000;88:162–168
  32. Loehrer PJ, Lauer R, Roth BJ, et al.  Salvage therapy in recurrent germ cell cancer: Ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med. 1988;109:540–546
  33. Motzer RJ, Cooper K, Geller NL, et al.  The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer. 1990;66:2476–2481
  34. Kantoff P, Halabi S, Conaway M, et al.  Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the CALGB 9182 study. J Clin Oncol. 1999;17:2506–2513
  35. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1:710–719
  36. Thalmann GN, Sikes RA, Chang SM, et al.  Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst. 1996;88:794–801
  37. Klotz LH. PSAdynia and other PSA-related syndromes: A new epidemic—A case history and toxonomy. Urology. 1997;50:831–832
  38. Anonymous , European Group on Tumor Markers EGTM . Anticancer Res. 1999;19:2785–2820
  39. Hayes DF, Bast R, Desch CE, et al.  A tumor marker utility grading system (TMUGS): A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996;88:1456–1466
  40. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol. 2001;19:2334–2356

☆ Address reprint requests to Ian F. Tannock, MD, Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Ave, Toronto, Ontario M5G 2M9, Canada.

PII: S0093-7754(02)50185-8

doi: 10.1053/sonc.2002.32904

Seminars in Oncology
Volume 29, Issue 3 , Pages 286-293 , June 2002

Article Tools

* Image Usage & Resolution